Preclinical Evaluation of In Vitro and In Vivo Antiviral Activities of KCT-01, a New Herbal Formula against Hepatitis B Virus

Figure 2

Suppression of HBsAg and HBeAg secretion by KCT-01 in HepG2.2.15 cells. (a-b) HepG2.2.15 cells were treated with increasing amounts of KCT-01 for 48 h. Amounts of HBsAg (a) and HBeAg (b) in culture supernatants were analyzed by ELISA. (c-d) HepG2.2.15 cells were treated with different concentrations of KCT-01 with ETV. Secreted amounts of HBsAg (c) and HBeAg (d) were analyzed by ELISA. Values are provided as mean ± S.D. of triplicated experiments. Statistical significance was processed using Student’s t-test. p < 0.01 and p < 0.001 compared to control conditions; p < 0.05 and p < 0.001 compared to ETV (25 μg/ml-) treated group; p < 0.01 and p < 0.001 compared to ETV (100 μg/ml-) treated group.